LFB S.A. Receives Go Ahead From Data Monitoring Committee to Expand The Global PERSEPT Phase 3 Program of LR769 in Hemophilia A or B Patients with Inhibitors

PARIS, France, March 24, 2015 —LFB SA announced today, through its rEVO Biologics subsidiary, that after the planned interim analysis of the PerSept 1 safety and efficacy data by the independent Data Monitoring Committee (DMC), the DMC recommended that the study proceed as planned and also that LFB should expand the global PerSept Phase 3 program. 

LFB S.A. Announces Achievement of Patient Enrollment Target for PerSept 1 Program for the Evaluation of Recombinant Factor Seven Efficacy by Prospective Clinical Trials

PARIS, France, December 17, 2014 — LFB S.A. announced today the achievement of patient enrollment target for PERSEPT 1, a multinational Phase 3 clinical trial of LR769, a novel recombinant form of human Factor VIIa, in adolescent and adult congenital hemophilia A or B patients with inhibitors.

This Phase 3 trial study is being sponsored by LFB S.A.’s US subsidiary.

LFB S.A. Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with inhibitors

FRAMINGHAM, MA, May 14, 2014 - LFB S.A., through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients with congenital hemophilia A or B with inhibitors. 

LFB S.A. Initiates Global Phase 3 Clinical Trial of New Coagulation Factor VIIA (Recombinant) in Patients with Hemophilia A and B

FRAMINGHAM, MA, March 3, 2014 —LFB S.A., through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors. 
 
LR769 was developed using rPRO™ technology and is being developed for treatment and prevention of bleeding episodes in hemophilia A and B patients with inhibitors to Factor VIII or IX.   
 

New Coagulation Factor VIIa (Recombinant) Shows Dose Response and is Well Tolerated in Patients with Hemophilia A and B (with or without inhibitors). Multicenter Study Results Presented at ISTH

FRAMINGHAM, Mass, July 1, 2013 —rEVO Biologics, an LFB company, announced positive preliminary results of a key dose ranging study, which demonstrates that LR769, a novel recombinant form of human Factor VIIa (rhFVIIa), is biologically active and well tolerated in patients with congenital hemophilia A or B at the three dosages tested.
 

rEVO Biologics, an LFB Company, Announces Completion of a Dose Ranging Study of a Novel, Recombinant Form of Factor VIIa in Patients with Hemophilia A and B

FRAMINGHAM, Mass, June 10, 2013 —rEVO Biologics, an LFB Company, announced today that it has completed the treatment and follow up phase of a key dose ranging study of LR769, a novel recombinant form of human Factor VIIa (rhFVIIa), in patients with congenital hemophilia A or B. Results from the study will be presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH), which takes place June 29–July 4, 2013, in Amsterdam, The Netherlands.